Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ATAPAC Study (TauroLock Activity in Adult Cancer Patients)

NCT: NCT02279121 · COMPLETED

NCT IDNCT02279121
StatusCOMPLETED
Start Date2014-11
Completion2016-03
SponsorCentre Hospitalier Régional Metz-Thionville (OTHER)
First posted
Last updated

Brief Summary

The purpose of this study is to compare the efficacy of a lock taurolidine-citrate solution vs standard saline solution for primary prevention of central venous catheter-associated bloodstream infection in adult patients treated with intra-venous therapy for a solid tumor

Frequently Asked Questions

What is ATAPAC Study (TauroLock Activity in Adult Cancer Patients)?

ATAPAC Study (TauroLock Activity in Adult Cancer Patients) is a clinical trial registered under NCT02279121. Current status: COMPLETED.

What is the status of NCT02279121?

The current status of NCT02279121 (ATAPAC Study (TauroLock Activity in Adult Cancer Patients)) is: COMPLETED.

When did ATAPAC Study (TauroLock Activity in Adult Cancer Patients) start?

ATAPAC Study (TauroLock Activity in Adult Cancer Patients) started on 2014-11.

Related Devices

K152819Amecath Peripheral inserted Central Venous Catheter SetsAmeco Medical Industries K171994Silicone Peripherally Inserted Central Venous Catheter Set/TrayCook Incorporated K172423PediaSat Oximetry Catheter, PreSep Oligon Oximetry Catheter, Edwards Oximetry Central Venous Catheter (previously PreSep Oximetry Catheter)Edwards Lifescience, LLC K182252Cook Unimpregnated Central Venous CatheterCook Incorporated K193158ACENT™ Central Venous CatheterGlobal Medikit Limited

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑